Saturday 14 February 2026

One To Watch

Akebia Therapeutics

A fully integrated biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease.

Company Overview

Want to Update your Company's Profile?


Latest Akebia Therapeutics News

Q32 Bio skyrockets as it sells complement inhibitor ADX-097
1 December 2025
The week in pharma: action, reaction and insight – week to October 31
2 November 2025
FDA setback prompts Akebia to give up on broader Vafseo label
29 October 2025
EC approves Averoa’s Xoanacyl for CKD
16 June 2025
More Akebia Therapeutics news >


Today's issue

Withdrawal of EU approvals for levamisole medicines recommended
Pharmaceutical
Withdrawal of EU approvals for levamisole medicines recommended
13 February 2026
Pharmaceutical
Vertex veers upwards on impressive results
13 February 2026
Pharmaceutical
Serum Institute of India inks deal with Oxford University
13 February 2026
Biotechnology
Moderna tops Q4 2025 EPS by 51c, beats on revenue
13 February 2026
Pharmaceutical
Breztri asthma results published with filings under review
13 February 2026
Biotechnology
Immunic prices private placement of up to $400 million
13 February 2026
Biosimilars
STADA and Bio-Thera win EC nod for Simponi biosimilar
13 February 2026


Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze